Original Publication Date: 18 February, 2016
Publication / Source: Melanoma Management
Authors: Constance Brinckerhoff
In a recent article published in Matrix Biology, M Jenkins, W Croteau, D Mullins and I described the effect of the mutant BRAFV600E inhibitor, vemurafenib/PLX4032, on collagen synthesis in melanoma cells . We found that this small molecule inhibitor, which blocks the sequential MAPK, RAS, RAF, MEK, ERK signaling pathway [2–4], substantially increased the synthesis of type I collagen in several human and murine melanoma cell lines.